MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Huang, Yurong; Hu, Quan; Deng, Zhenghua; Hang, Yonglun; Wang, Jie; Wang, Kaizheng

doi:10.7785/tcrt.2012.500377

Cited by 26 publications

(20 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our review suggests that circulating miRNAs have great potential to be used as markers for LC detection and may be promising candidates for general cancer screening. Compared to previous reviews, 39,[58][59][60][61][62][63][64][65] we employed a broader inclusion criterion by including all histological types of LC cases, and we focused on studies conducted in Western populations in order to reduce a primary source of heterogeneity in miRNAs profiles. Although previous reviews have reported tremendous heterogeneity in included studies and inconsistency in LC-related miRNA markers, very few reviews explored the sources of the heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNA biomarkers for lung cancer detection in Western populations

Guan

Ćuk

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Lung cancer (LC) is a leading cause of cancer‐related death in the Western world. Patients with LC usually have poor prognosis due to the difficulties in detecting tumors at early stages. Multiple studies have shown that circulating miRNAs might be promising biomarkers for early detection of LC. We aimed to provide an overview of published studies on circulating miRNA markers for early detection of LC and to summarize their diagnostic performance in Western populations. A systematic literature search was performed in PubMed and ISI Web of Knowledge to find relevant studies published up to 11 August 2017. Information on study design, population characteristics, miRNA markers, and diagnostic accuracy (including sensitivity, specificity, and AUC) were independently extracted by two reviewers. Overall, 17 studies evaluating 35 circulating miRNA markers and 19 miRNA panels in serum or plasma were included. The median sensitivity (range) and specificity (range) were, respectively, 78.4% (51.7%‐100%) and 78.7% (42.9%‐93.5%) for individual miRNAs, and 83.0% (64.0%‐100%) and 84.9% (71.0%‐100%) for miRNA panels. Most studies incorporated individual miRNA markers as panels (with 2‐34 markers), with multiple miRNA‐based panels generally outperforming individual markers. Two promising miRNA panels were discovered and verified in prospective cohorts. Of note, both studies exclusively applied miRNA ratios when building up panels. In conclusion, circulating miRNAs may bear potential for noninvasive LC screening, but large studies conducted in screening or longitudinal settings are needed to validate the promising results and optimize the marker panels.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating microRNA biomarkers for lung cancer detection in Western populations

Guan

Ćuk

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Circulating miRNA biomarkers have been reported in many diseases including those involving the lungs11. Since miRNA in circulating blood is considered to be a non-invasive measurement and can be an indication of specific disease conditions, circulating miRNA may be considered for development of biomarkers.…”

Section: Changes In Mirna Associated With Irradiated Lungsmentioning

confidence: 99%

Changes in miRNA in the lung and whole blood after whole thorax irradiation in rats

Gao

Liu

Narayanan

et al. 2017

Sci Rep

View full text Add to dashboard Cite

We used a rat model of whole thorax x-ray irradiation to profile the microRNA (miRNA) in lung and blood up to 4 weeks after radiation. MiRNA from normal and irradiated Wistar rat lungs and whole blood were analyzed by next-generation sequencing and the changes by radiation were identified by differential deRNA-seq 1, 2, 3 and 4 weeks after irradiation. The average total reads/library was 2,703,137 with a mean of 88% mapping to the rat genome. Detailed profiles of 100 of the most abundant miRNA in rat blood and lung are described. We identified upregulation of 4 miRNA, miR-144-5p, miR-144-3p, miR-142-5p and miR-19a-3p in rat blood 2 weeks after radiation that have not previously been shown to be altered after radiation to the lung. Ingenuity Pathway Analysis identified signaling of inflammatory response pathways. These findings will support development of early detection methods, as well as mechanism(s) of injury and mitigation in patients after radiotherapy or radiological accidents.

show abstract

“…Extracellular miRNAs are remarkably stable in the circulation [35][36][37]40]. As a result of cellular damage/tissue injury, such as in acute myocardial infarction (MI) [41][42][43], atherosclerosis [44], nonsmall cell lung cancer [45], neurodegenerative diseases [46][47][48][49], skin fibrosis [50] and osteoarthritis [51] (Table 1), miRNA expression can change in the blood. Notably, this list is increasingly expanding.…”

mentioning

confidence: 99%

Methodological challenges in utilizing miRNAs as circulating biomarkers

Moldovan

Batte

Trgovcich

et al. 2014

J Cellular Molecular Medi

360

338

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have emerged as important regulators in the post-transcriptional control of gene expression. The discovery of their presence not only in tissues but also in extratissular fluids, including blood, urine and cerebro-spinal fluid, together with their changes in expression in various pathological conditions, has implicated these extracellular miRNAs as informative biomarkers of disease. However, exploiting miRNAs in this capacity requires methodological rigour. Here, we report several key procedural aspects of miRNA isolation from plasma and serum, as exemplified by research in cardiovascular and pulmonary diseases. We also highlight the advantages and disadvantages of various profiling methods to determine the expression levels of plasma-and serum-derived miRNAs. Attention to such methodological details is critical, as circulating miRNAs become diagnostic tools for various human diseases.

show abstract

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Cited by 26 publications

References 50 publications

Circulating microRNA biomarkers for lung cancer detection in Western populations

Circulating microRNA biomarkers for lung cancer detection in Western populations

Changes in miRNA in the lung and whole blood after whole thorax irradiation in rats

Methodological challenges in utilizing miRNAs as circulating biomarkers

Contact Info

Product

Resources

About